๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

1424 SYNERGISTIC INTERACTIONS OF HCV NS5A REPLICATION COMPLEX INHIBITORS SENSITIZE RESISTANT VARIANTS AND ENHANCE THE EFFICACY OF DACLATASVIR (DCV, BMS-790052) IN VITRO AND IN VIVO

โœ Scribed by Gao, M.; O'Boyle, D.R.; Lemm, J.A.; Fridell, R.A.; Wang, C.; Roberts, S.; Liu, M.; Nower, P.; Wang, Y.-K.; Johnson, B.M.; Kramer, M.; Moulin, F.; Nophsker, M.J.; Hewawasam, P.; Kadow, J.; Cockett, M.; Meanwell, N.A.; Belema, M.; Sun, J.-H.


Book ID
122810811
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
221 KB
Volume
58
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Genotypic and phenotypic analysis of var
โœ Robert A. Fridell; Chunfu Wang; Jin-Hua Sun; Donald R. O'Boyle II; Peter Nower; ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 338 KB ๐Ÿ‘ 1 views

The NS5A replication complex inhibitor, BMS-790052, inhibits hepatitis C virus (HCV) replication with picomolar potency in preclinical assays. This potency translated in vivo to a substantial antiviral effect in a single-ascending dose study and a 14-day multiple-ascending dose (MAD) monotherapy stu